Huatai Zijin Chen Miao: A Platform Enterprise With An Independent Investment In R & D Capability.

"We tend to choose a platform based enterprise with independent R & D capability, and its ability to resist risks will be stronger. At the same time, an excellent management team can help companies resolve crises and seize opportunities. Recently, Chen Miao, partner of Huatai Zijin, said in an interview with the twenty-first Century economic report.

He said, for example, during the epidemic period, three diagnostic firms of Huatai invested have obtained the registration certificate of the new crown diagnostic kit, which has contributed to the country's fight against the disease while breaking its own performance.

Huatai Zijin Chen Miao. Data map

It is understood that Huatai Zijin was founded in 2008, is a subsidiary of Huatai Securities specializing in equity investment business. At present, the fund management scale is nearly fifty billion yuan, and the medical and health field is one of the main tracks. Chen Miao is mainly responsible for investment in medicine and diagnostics.

In Chen Miao's view, the advantage of the broker's background is that it relies on the parent company's Huatai Securities Research Institute and investment bank resources. On the one hand, the industry research understanding of the team will be more thorough. On the other hand, the team is more familiar with the sponsor issuing system of the domestic capital market. But at the same time, the direct investment of brokerages will be tighter regulated than ordinary social private institutions, with a focus on the firewall between investment and investment banking.

At present, Huatai Zijin has three main directions in medicine, medical devices and medical services. From the perspective of investment weights, the team invested most in the field of medicine, followed by medical devices and medical services, which is also positively related to the scale of the industry.

"Diagnostic plate is the area where Huatai has done more." Chen Miao said. In terms of the diagnostic items, MINDRAY medical, Shuo Shi, basic egg organisms and Pu men technology have been listed. Shihe gene, nuwei Zan, pioneer diagnosis, Berger medical care and other companies are also actively preparing for the declaration, basically realizing the full coverage of immune POCT, chemiluminescence, molecular diagnosis, NGS and other sub sectors.

In screening and judging projects, Huatai Zijin also summed up some common standards. For example, the market size of the company is large enough, the management team should be excellent enough, and at the same time, the company itself has high technical barriers.

Turning to the impact of the epidemic on the health care industry, Chen Miao said that the outbreak of the epidemic made the whole country and the whole world reexamine the great harm of pathogenic microorganisms, the important role of prevention and control of infectious diseases, and the short layout in the field of health care. Governments at all levels are constantly increasing investment in medical and health fields. In the future, there will be more investment opportunities in the direction of diagnosis, therapeutic drugs and vaccines.

?